Seattle Genetics

Seattle Genetics to acquire Cascadian along with HER2-targeted breast cancer drug tucatinib

Seattle Genetics and Cascadian Therapeutics sign a definitive merger agreement under which Seattle Genetics has agreed to acquire Cascadian. Cascadian’s most advanced program is tucatinib, an oral, small molecule tyrosine kinase inhibitor that is highly selective for human epidermal growth factor receptor 2 (HER2). Tucatinib is currently being evaluated in the randomized, global, pivotal trial HER2CLIMB for patients with HER2-positive (HER2+) metastatic breast cancer, including patients with or without brain metastases. Tucatinib has been evaluated as a single agent and in combination with both chemotherapy and other HER2-directed agents including trastuzumab and trastuzumab emtansine.

Click here to go to the full article

Are you ready to explore new ideas?

Learn the many ways TRM Oncology can support you and your valued stakeholders.

All Fields Required